 PITTSBURGH, Sept. 09, 2021 GLOBE NEWSWIRE -- Krystal Biotech Inc., Krystal NASDAQ: KRYS, the leader in redosable gene therapies for rare diseases, today announced that it will present data on its lead product candidate beremagene geperpavec B-VEC for the treatment of dystrophic epidermolysis bullosa DEB at the upcoming DEBRA International Conference 2021. Data to be presented includes preclinical evidence of safety and collagen VII expression after topical B-VEC application to induced corneal wounds. This preclinical study was conducted in response to a compassionate use request from a physician for the use of topical eye drop B-VEC in the eye of a single recessive DEB patient after undergoing surgical removal of the scared layer of the cornea. The U.S. FDA recently approved the physicians request. 